Podcast: Kiran Mazumdar – Shaw speaks to ET Now on strong performance of biosimilars business and Biocon Biologics’ growth prospects.

Biocon CMD Kiran Mazumdar-Shaw tells ET Now in an interview that the Company remains extremely confident of delivering very strong numbers in its Biologics business this fiscal, with a more robust performance in the second half of the year on the back of the commercialization of biosimilar Trastuzumab in the U.S. market. She also talks … Continue reading Podcast: Kiran Mazumdar – Shaw speaks to ET Now on strong performance of biosimilars business and Biocon Biologics’ growth prospects.